AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01258049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether Sublingual Spray
Description: Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
Study NCT01258049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
Study NCT04410393 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal cuff prolapse surgery
Description: Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
Study NCT03252158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Availability of healthier vs. less healthy foods
Description: Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2\&3 and 5\&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7).
Study NCT04451096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics with prebiotic
Description: Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
Study NCT04451096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
Study NCT01339065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
Study NCT01339065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
Study NCT02585440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: Oral tablet
Study NCT02585440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral tablet
Study NCT00284856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 10 mg tablet once daily, 6 month treatment period
Study NCT00284856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
Study NCT00284856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
Study NCT00284856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: fluticasone
Description: fluticasone propionate 250 mcg twice daily, 6 month treatment period
Study NCT00284856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo
Description: montelukast 10 mg Pbo tablet once daily, 6 month treatment period
Study NCT00284856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: montelukast 10 mg Pbo tablet once daily, 6 month treatment period
Study NCT05359484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uroflowmetry
Description: according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
Study NCT05017844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KSR-001-04
Description: One drop to both eyes four times a day for 12 weeks
Study NCT05017844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001-02
Description: One drop to both eyes four times a day for 12 weeks
Study NCT05017844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001-03
Description: One drop to both eyes four times a day for 12 weeks
Study NCT00764634 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (USP sterile saline for injection)
Description: 0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
Study NCT00764634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rBV A/B-40 vaccine
Description: 0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
Study NCT00764634 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (USP sterile saline for injection)
Description: 0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
Study NCT00764634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rBV A/B-40 vaccine
Description: 0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
Study NCT03779646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate
Description: Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate \<75bpm and systolic blood pressure \<90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
Study NCT03886909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
Study NCT03886909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation Education
Description: Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
Study NCT04490408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long surgical bypass
Description: long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.
Study NCT04490408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid approach
Description: Hybrid approach including bypass and endovascular revascularization
Study NCT01553929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training and cognitive activity (EPC group)
Description: The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
Study NCT01553929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training (EP group)
Description: The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
Study NCT01553929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: no physical training and no cognitive activity
Study NCT02542969 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Study NCT02542969 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Study NCT02542969 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MGL-3196
Study NCT01494207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness counseling
Description: Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
Study NCT03184740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
Study NCT03184740 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
Study NCT02749409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Study NCT02749409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02592824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutamate infusion
Description: Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
Study NCT02592824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
Study NCT03057886 — intervention group
Intervention type: DEVICE
Intervention: Comparative thermometers to compare with a new device
Description: The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
Study NCT03720561 — intervention group
Intervention type: DRUG
Intervention: Ibrutinib
Description: Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
Study NCT01142336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg qHS for 1 year
Study NCT01142336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet qHS for 1 year
Study NCT01704261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 25 mg capsule administered orally once a week
Study NCT01704261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to Omarigliptin
Description: Matching placebo to omarigliptin capsule administered orally once a week
Study NCT01704261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
Study NCT01704261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
Study NCT01704261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
Study NCT01704261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
Study NCT04550299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical technique combined with a specific choice of the material for the ligament reconstruction
Description: The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
Study NCT03153670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
Study NCT00423046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)
Description: Three doses administered intramuscularly at months 0, 1 and 6
Study NCT00423046 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil ® (Merck & Co. Inc)
Description: Three doses administered intramuscularly at months 0, 2 and 6
Study NCT00423046 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One dose administered intramuscularly at month 1 to maintain blinding
Study NCT00423046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose administered intramuscularly at month 2 to maintain blinding
Study NCT01604785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
Study NCT01604785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Ketorolac, Diphenhydramine and Metoclopramide
Study NCT00879658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Study NCT00879658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Cognitive Remediation
Description: Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Cognitive Remediation
Description: Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Remediation Control
Description: The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online computer exercises
Description: There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online computer exercises
Description: There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Online computer exercises
Description: There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy monitoring
Description: Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strategy monitoring
Description: Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Strategy monitoring
Description: Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging strategies
Description: The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bridging strategies
Description: The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).